Eiger ends PhIII hepatitis delta trial over safety concerns — and the search for treatment partner
Eiger BioPharmaceuticals is ending a Phase III trial investigating its treatment in liver infections caused by the hepatitis D virus over safety concerns, just a few months after it laid off 25% of its employees and cut R&D spending to the program.
Eiger was investigating peginterferon lambda in patients with chronic hepatitis delta, a liver infection caused by the hepatitis D virus. Hepatitis D only occurs in people who are also infected with the hepatitis B virus, according to the CDC. It results in the most severe form of human viral hepatitis, for which there is no approved therapy.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.